BiondVax CEO Amir Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines HQ in Belgium until 2021. Prior to that, he served as Sr Director Global GSK Vaccines Supply Chain. Mr. Reichman joined GSK in 2015 after its acquisition of Novartis Vaccines. At Novartis Vaccines, he held various leadership roles of increasing responsibility in its Global Vaccines Supply Chain Management organization located in Holly Springs, NC, USA. In 2003, Mr. Reichman’s academic work at Ben-Gurion University of the Negev (BGU) contributed to the founding of NeuroDerm Ltd., a company focused on transdermal drug delivery systems that was acquired by Mitsubishi Tanabe Pharma in 2017 for $1.1B. He was NeuroDerm’s first employee and served as its Chief Engineer and Sr Scientist. Mr. Reichman earned an M.Sc. in Biotechnology Engineering from BGU, and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania, USA.